Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
over 20
years old
The phase for this study is not defined.
Show me locations

The purpose

This is a study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of DS-1001b in patients with gliomas that harbor IDH1-R132 mutations.

Provided treatments

  • Drug: DS-1001b
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03030066. The sponsor of the trial is Daiichi Sankyo Co., Ltd. and it is looking for 60 volunteers for the current phase.
Official trial title:
A Phase 1 Study of DS-1001b in Patients With IDH1 Mutated Gliomas